Jong Taek Kim
No Rating Available
(Learn About Our Rating System)

Jong Taek Kim, MD, MS

Languages spoken: English

Specialties

  • Pathology, Anatomical

Board Certification

American Board of Pathology (Sub: Molecular Genetic Pathology)
American Board of Pathology (Sub: Clinical Informatics)
American Board of Pathology (Anatomic & Clinical)
National Board of Medical Examiners

Board Certification and Academic Information

Academic Departments Pathology -Assistant Professor (Clinical)
Board Certification
American Board of Pathology (Sub: Molecular Genetic Pathology)
American Board of Pathology (Sub: Clinical Informatics)
American Board of Pathology (Anatomic & Clinical)
National Board of Medical Examiners

Education history

Undergraduate Major: Biology; Minor: Chemistry - University of Mississippi B.S.
Doctoral Training Medicine - University of South Alabama College of Medicine M.D.
Residency Orthopaedic Surgery - Medical University of South Carolina Resident
Residency Anatomic and Clinical Pathology - University of Florida College of Medicine Resident
Residency Anatomic and Clinical Pathology - University of Florida College of Medicine Co-Chief Resident
Graduate Training Biomedical Informatics - University of Florida College of Medicine M.S.
Fellowship Molecular Genetics Pathology - Cedars-Sinai Medical Center Fellow

Selected Publications

Journal Article

  1. Wilcock D, Sirohi D, Coleman JF, Adelhardt P, Kim JT, Albertson D, Affolter K, Beech C, Jedrzkiewicz J, Ruano AL, Cleary AS, Mahlow J, Balatico M, Gulbahce H (2025). HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry. American journal of clinical pathology, 163(6), 837-846.
  2. Beech C, Wilcock DM, Moore KH, Rowe L, Mahlow J, Jedrzkiewicz J, Cleary AS, Lomo L, Ruano AL, Gering M, Bradshaw D, Maughan M, Tran P, Davis R, Affolter K, Albertson DJ, Adelhardt P, Kim J, Coleman JF, Deftereos G, Gulbahce EH, Sirohi (2025). Changes in HER2 Amplification Status for Breast Cancer Patients After Immunohistochemistry Directed In Situ Hybridization. Applied immunohistochemistry & molecular morphology, 33(2), 91-102.
  3. Wilcock DM, Moore KH, Rowe L, Mahlow J, Jedrzkiewicz J, Cleary AS, Lomo L, Ruano AL, Gering M, Bradshaw D, Maughan M, Tran P, Burlingame J, Davis R, Affolter K, Albertson DJ, Adelhardt P, Kim JT, Coleman JF, Deftereos G, Gulbahce EH, Sirohi (2023). Quantitative Imaging Analysis Fluorescence In Situ Hybridization Validation for Clinical HER2 Testing in Breast Cancer. Archives of pathology & laboratory medicine,
  4. Wilcock DM, McMurtry V, Coleman JF, Kim JT, Khalili P, Deftereos G, Albertson D, Gulbahce EH, Liu T, Sirohi (2022). Histopathological Correlation of Chromosome 12 Polysomy by Fluorescence in Situ Hybridization in Adipocytic Neoplasms. International journal of surgical pathology, 30(7), 10668969221085289.
  5. Wong M, Kim JT, Cox B, Larson BK, Kim S, Waters KM, Vail E, Guindi (2021). Evaluation of Tumor Mutational Burden in Small Early Hepatocellular Carcinoma and Progressed Hepatocellular Carcinoma. Is There a Difference? . Hepatic oncology, 8(4), HEP39.
  6. Kim JT, Harris N (2019). Utilization Review of Paraneoplastic Neurological Syndrome Antibody Screening Panels: Experience at a Tertiary Academic Health Center. The journal of applied laboratory medicine, 4(1), 19-29.
  7. Shon W, Kim J, Sukov W, Reith J (2016). Malignant TFE3-rearranged perivascular epithelioid cell neoplasm (PEComa) presenting as a subcutaneous mass. Br J Dermatol, 174(3), 617-20.
  8. Kim JT, Rudolf LM, Glaser J (2013). Outcome of percutaneous sacroiliac joint fixation with porous plasma-coated triangular titanium implants: an independent review. The open orthopaedics journal, 7, 51-6.
  9. Grishko V, Xu M, Ho R, Mates A, Watson S, Kim JT, Wilson GL, Pearsall AW 4th (2009). Effects of hyaluronic acid on mitochondrial function and mitochondria-driven apoptosis following oxidative stress in human chondrocytes. J Biol Chem, 284(14), 9132-9.

Case Report

  1. Taek Kim J, Zhang W, Lopategui J, Vail E, Balmanoukian (2021). Patient With Stage IV NSCLC and CNS Metastasis With EGFR Exon 18-25 Kinase Domain Duplication With Response to Osimertinib as a First-Line Therapy. JCO precision oncology, 5, 88-92.
  2. Gower A, Kim J, Spector K, Menashe D, Vail E, Natale (2021). Three Primary Tumors Including EGFR-mutated Non-Small Cell Lung Cancer as First Presentation in Patient With Li-Fraumeni Syndrome. Clinical lung cancer, 22(1), e116-e121.

Letter

  1. Kim JT, Winter WE, Luo HY, Chui DHK, Harris N (2019). Interference of Hemoglobin A1c Due to Hemoglobin Franklin Park. The journal of applied laboratory medicine, 3(5), 911-913.
  2. Kim JT, Newsom KJ, Shon W (2018). Detection of somatic mutations in secondary tumors associated with nevus sebaceus by targeted next generation sequencing. Comment on Kitamura et al. [Letter to the editor]. Int J Dermatol, 57(1), 120-122.

Other

  1. Vail E, Song J, Xu J, Frye JS, Kim JT, Pao A, Schreck R, Aguiluz AS, Zhang W, Alkan S, Mita A, Mita M, Figlin RA, Engman DM, Lopategui J (2020). Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer. Targeted oncology, 15(4), 523-530.
  2. Zhang W, Govindavari JP, Davis BD, Chen SS, Kim JT, Song J, Lopategui J, Plummer JT, Vail (2020). Analysis of Genomic Characteristics and Transmission Routes of Patients With Confirmed SARS-CoV-2 in Southern California During the Early Stage of the US COVID-19 Pandemic. JAMA network open, 3(10), e2024191.